CO4970724A1 - Terapia de combinacion - Google Patents

Terapia de combinacion

Info

Publication number
CO4970724A1
CO4970724A1 CO98049139A CO98049139A CO4970724A1 CO 4970724 A1 CO4970724 A1 CO 4970724A1 CO 98049139 A CO98049139 A CO 98049139A CO 98049139 A CO98049139 A CO 98049139A CO 4970724 A1 CO4970724 A1 CO 4970724A1
Authority
CO
Colombia
Prior art keywords
combinations
hyperlipidemia
atherosclerosis
hypertension
subjects
Prior art date
Application number
CO98049139A
Other languages
English (en)
Inventor
Scott Robert Andrew Donald
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO4970724A1 publication Critical patent/CO4970724A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Esta invención se refiere a combinaciones farmacéuticas deatorvastatina o una sal farmacéuticamente aceptable de la misma y agentes antihipertensores, estuches de ensayo que contienen dichas combinaciones y procedimientos para utilizar dichas combinaciones para tratar sujetos que sufren de angina pectoris, ateroesclerosis, hipertensión e hiperlipidemia combinadas y para tratar sujetos que presenten síntomas de riesgo cardíaco, incluyendo seres humanos. Esta invención se refiere también a combinaciones aditivas y sinérgicas de atorvastatina o una sal farmacéuticamente aceptable de la misma y agentes antihipertensores por los que estas combinaciones sinérgicas son útiles en el tratamiento de sujetos que sufren de angina pectoris, ateroesclerosis, hipertensión e hiperlipidemia combinadas y aquellos sujetos que presenten síntomas de riesgo cardíaco, incluyendo los seres humanos.
CO98049139A 1997-08-29 1998-08-27 Terapia de combinacion CO4970724A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
CO4970724A1 true CO4970724A1 (es) 2000-11-07

Family

ID=22009602

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98049139A CO4970724A1 (es) 1997-08-29 1998-08-27 Terapia de combinacion

Country Status (41)

Country Link
US (2) US20020099046A1 (es)
EP (1) EP1009400B1 (es)
JP (2) JP2001514223A (es)
KR (3) KR20040106591A (es)
CN (3) CN1473566A (es)
AP (1) AP1191A (es)
AR (1) AR016399A1 (es)
AT (1) ATE285767T1 (es)
AU (1) AU740424B2 (es)
BG (1) BG64724B1 (es)
BR (1) BR9811556A (es)
CA (1) CA2296723A1 (es)
CO (1) CO4970724A1 (es)
DE (1) DE69828413T2 (es)
DZ (1) DZ2595A1 (es)
EA (1) EA200000012A1 (es)
EG (1) EG24678A (es)
ES (1) ES2234134T3 (es)
GT (1) GT199800126A (es)
HR (1) HRP980474A2 (es)
HU (1) HUP0004318A3 (es)
ID (1) ID24118A (es)
IL (2) IL133962A0 (es)
IS (1) IS5341A (es)
MA (1) MA26536A1 (es)
MY (1) MY121008A (es)
NO (1) NO323987B1 (es)
NZ (2) NZ502280A (es)
OA (1) OA11291A (es)
PA (1) PA8457901A1 (es)
PE (1) PE107099A1 (es)
PL (1) PL339091A1 (es)
PT (1) PT1009400E (es)
SA (1) SA98190603B1 (es)
SK (1) SK1432000A3 (es)
TN (1) TNSN98155A1 (es)
TR (1) TR200000563T2 (es)
UY (1) UY25155A1 (es)
WO (1) WO1999011260A1 (es)
YU (1) YU2000A (es)
ZA (1) ZA987839B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
KR20010041916A (ko) * 1998-03-17 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
US7125897B1 (en) 1999-09-24 2006-10-24 Vasogen Ireland Limited Combined therapies for atherosclerosis treatment
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
EP1313714B1 (en) 2000-07-19 2008-08-27 Novartis AG Valsartan salts
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
MXPA04000586A (es) * 2001-07-19 2004-04-20 Pharmacia Corp Combinacion de un atagonista del receptor de aldosterona con un inhibidor de la hmg coa reductasa.
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ES2304521T3 (es) * 2002-06-20 2008-10-16 The Governors Of The University Of Alberta Dicloroacetato en combinacion con farmacos cardioprotectores o hemodinamicos.
BR0312102A (pt) * 2002-06-27 2007-05-29 Sb Pharmco Inc sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
EP1553941A1 (en) * 2002-10-16 2005-07-20 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
JP5072364B2 (ja) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
US20070191438A1 (en) * 2004-04-06 2007-08-16 Rohrer Susan P Methods for the treatment of hypertension
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
EP2208496A1 (en) * 2004-08-25 2010-07-21 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
WO2006087117A1 (en) * 2005-02-17 2006-08-24 Chiesi Farmaceutici S.P.A. Therapeutic combinations of manidi pine and a statin
CN101415425B (zh) 2006-03-29 2014-11-26 兴和株式会社 甘油三酯降低剂和高胰岛素血症改善剂
KR100985254B1 (ko) * 2006-10-30 2010-10-04 한올바이오파마주식회사 방출성이 제어된 안지오텐신―Ⅱ―수용체 차단제와ＨＭＧ―ＣｏＡ 환원 효소 억제제의 복합 조성물
CN102065847A (zh) 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
EP2413931B1 (en) * 2009-01-23 2016-06-01 Hanmi Science Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
MX2015012666A (es) * 2013-03-12 2016-02-16 Lg Life Sciences Ltd Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo.
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
MX2021009909A (es) 2014-10-23 2022-07-25 Arena Pharm Inc Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
CN112933093A (zh) * 2015-06-30 2021-06-11 韩美药品株式会社 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
AU2017274438A1 (en) * 2016-06-02 2018-12-13 Ana Pharmaceuticals, Inc. Methods and compositions for treatment of hypercalciuria and nephrolithiasis
BR112019015368A2 (pt) 2017-01-25 2020-03-10 The George Institute for Global Health Composições para o tratamento de hipertensão
AU2018227842A1 (en) 2017-03-01 2019-09-19 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof
US20200030296A1 (en) * 2018-07-26 2020-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
CA2180296C (en) * 1995-07-03 2007-01-09 Yoshio Tsujita Treatment of arteriosclerosis and xanthoma
RO120816B1 (ro) * 1995-11-02 2006-08-30 Warner-Lambert Company COMPOZIŢIE FARMACEUTICĂ PE BAZĂ DE INHIBITOR DE ACIL-CoA COLESTEROL O-ACIL-TRANSFERAZEI ŞI INHIBITOR AL REDUCTAZEI HMG-CoA şi UTILIZAREA ACESTEIA

Also Published As

Publication number Publication date
JP2005041875A (ja) 2005-02-17
AR016399A1 (es) 2001-07-04
IS5341A (is) 2000-01-14
ES2234134T3 (es) 2005-06-16
MY121008A (en) 2005-12-30
WO1999011260A1 (en) 1999-03-11
EP1009400B1 (en) 2004-12-29
AP9801332A0 (en) 1998-09-30
NO323987B1 (no) 2007-07-30
DE69828413D1 (de) 2005-02-03
OA11291A (en) 2003-08-25
IL133962A0 (en) 2001-04-30
PL339091A1 (en) 2000-12-04
AU8458998A (en) 1999-03-22
KR20040106591A (ko) 2004-12-17
BG104075A (en) 2000-09-29
MA26536A1 (fr) 2004-12-20
PE107099A1 (es) 1999-11-06
AU740424B2 (en) 2001-11-01
CN1268053A (zh) 2000-09-27
GT199800126A (es) 2000-01-29
BR9811556A (pt) 2000-08-22
ATE285767T1 (de) 2005-01-15
DZ2595A1 (fr) 2003-02-22
NZ502280A (en) 2002-11-26
NO20000996L (no) 2000-04-27
CN1473566A (zh) 2004-02-11
TNSN98155A1 (fr) 2005-03-15
KR20010022477A (ko) 2001-03-15
YU2000A (sh) 2002-12-10
DE69828413T2 (de) 2005-12-08
NO20000996D0 (no) 2000-02-28
EG24678A (en) 2010-04-27
EA200000012A1 (ru) 2000-08-28
US20020099046A1 (en) 2002-07-25
US20030199492A1 (en) 2003-10-23
EP1009400A1 (en) 2000-06-21
HRP980474A2 (en) 1999-06-30
ZA987839B (en) 2000-02-28
UY25155A1 (es) 2000-12-29
ID24118A (id) 2000-07-06
CA2296723A1 (en) 1999-03-11
HUP0004318A3 (en) 2002-10-28
TR200000563T2 (tr) 2000-07-21
AP1191A (en) 2003-07-19
KR20030015394A (ko) 2003-02-20
SK1432000A3 (en) 2000-12-11
BG64724B1 (bg) 2006-01-31
PA8457901A1 (es) 2000-05-24
PT1009400E (pt) 2005-02-28
JP2001514223A (ja) 2001-09-11
SA98190603B1 (ar) 2006-07-04
NZ530630A (en) 2005-05-27
CN1473567A (zh) 2004-02-11
HUP0004318A2 (hu) 2001-05-28
IL133962A (en) 2006-07-05

Similar Documents

Publication Publication Date Title
CO4970724A1 (es) Terapia de combinacion
CO4970694A1 (es) Amlodipino y atorvastatina utiles en el tratamiento de angina de pecho, ateroesclerosis, hipertension e hiperlipidemia
CO4970726A1 (es) Terapia de combinacion pino y atorvastatina utiles en el tratamiento de angina de pecho, ateroesclerosis,hipertension e hiperlipidemia
PT1014961E (pt) Tratamento da cefaleia de enxaqueca utilizando metoclopramida e um nsaid
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
EA200100573A1 (ru) Применение ингибитора циклооксигеназы-2, ингибитора матричной металлопротеиназы, противоопухолевого лекарственного средства и факультативно облучения в качестве комбинированного способа лечения неоплазии
CY1106149T1 (el) Η χρηση ενωσεων υποκατεστημενης αζετιδινονης για την θepαπεια σιτοστepολαιμιας
ES2178157T3 (es) Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
DK1035859T3 (da) Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler
ECSP982647A (es) Terapia de combinacion
ES2186153T3 (es) Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.
ECSP982645A (es) Terapia de combinacion
UY27510A1 (es) Terapia de combinación
ECSP982646A (es) Combinaciones terapeuticas
BR0013665A (pt) Uso de uma proteìna histacalina, composição farmacêutica, e, método de tratar ou impedir conjuntivite
ECSP003497A (es) Sal mutua de amlodipino y atorvastatina